Mallinckrodt (MNK) Getting Somewhat Positive News Coverage, Study Finds
Media coverage about Mallinckrodt (NYSE:MNK) has been trending somewhat positive this week, according to Accern. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Mallinckrodt earned a daily sentiment score of 0.11 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.693886799662 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Mallinckrodt (MNK) opened at $22.30 on Friday. The company has a current ratio of 1.38, a quick ratio of 1.05 and a debt-to-equity ratio of 1.08. Mallinckrodt has a 12-month low of $19.00 and a 12-month high of $55.32. The firm has a market capitalization of $2,018.85, a P/E ratio of 2.87, a PEG ratio of 0.39 and a beta of 1.30.
Mallinckrodt (NYSE:MNK) last issued its earnings results on Tuesday, November 7th. The company reported $1.97 earnings per share for the quarter, topping analysts’ consensus estimates of $1.80 by $0.17. Mallinckrodt had a return on equity of 14.79% and a net margin of 11.43%. The company had revenue of $793.90 million for the quarter, compared to analyst estimates of $808.93 million. During the same period in the prior year, the firm earned $2.04 earnings per share. Mallinckrodt’s revenue for the quarter was down 10.5% on a year-over-year basis. research analysts predict that Mallinckrodt will post 7.2 EPS for the current fiscal year.
MNK has been the topic of several recent analyst reports. Stifel Nicolaus dropped their price target on Mallinckrodt from $70.00 to $50.00 and set a “buy” rating on the stock in a research note on Wednesday, November 8th. Zacks Investment Research lowered Mallinckrodt from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Piper Jaffray Companies set a $67.00 price target on Mallinckrodt and gave the company a “buy” rating in a research note on Saturday, October 21st. Jefferies Group reissued a “buy” rating and issued a $60.00 price target on shares of Mallinckrodt in a research note on Friday, October 6th. Finally, UBS set a $70.00 price target on Mallinckrodt and gave the company a “buy” rating in a research note on Friday, October 6th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $48.14.
In other news, General Counsel Michael-Bryant Hicks bought 7,900 shares of the stock in a transaction dated Thursday, November 9th. The shares were bought at an average cost of $20.80 per share, with a total value of $164,320.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David R. Carlucci purchased 10,000 shares of the stock in a transaction that occurred on Thursday, November 9th. The stock was bought at an average cost of $21.83 per share, with a total value of $218,300.00. Following the completion of the transaction, the director now directly owns 26,020 shares in the company, valued at approximately $568,016.60. The disclosure for this purchase can be found here. Insiders have bought 30,460 shares of company stock worth $659,486 over the last ninety days. 0.77% of the stock is owned by insiders.
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
Receive News & Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.